参考文献/References:
[1]Long K,Danoff SK.Interstitial Lung Disease in Polymyositis and Dermatomyositis[J].Clin Chest Med,2019,40(3):561-572. [2]Sun Y,Liu Y,Yan B,et al.Interstitial lung disease in clinically amyopathic dermatomyositis(CADM)patients:a retrospective study of 41 Chinese Han patients[J].Rheumatology International,2013,33(5):1295-1302. [3]Sato S,Hirakata M,Kuwana M,et al.Autoantibodies to a 140-kd polypeptide,CADM-140,in Japanese patients with clinically amyopathic dermatomyositis[J].Arthritis&Rheumatism,2010,52(5):1571-1576. [4]Sato S,Hoshino K,Satoh T,et al.RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis:Association with rapidly progressive interstitial lung disease[J].Arthritis Rheum,2009,60(7):2193-2200. [5]程玉强.鸡MDA5-STING-IFN-β抗病毒天然免疫通路的发现及其信号转导机制[D].上海交通大学,2016. [6]曹华,夏群力,亢延卿,等.抗黑素瘤分化相关基因5抗体评价皮肌炎/临床无肌病性皮肌炎合并肺间质病变的病情及预后的研究[J].中华风湿病学杂志,2014,18(5):329-331. [7]Takada T,Ohashi K,Hayashi M,et al.Role of IL-15 in interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibody[J].Respiratory Medicine,2018(141):7-13. [8]Louise E,Michelle KJ,Sevim BH,et al.Dysfunction of endothelial progenitor cells is associated with the type I IFN pathway in patients with polymyositis and dermatomyositis[J].Rheumatology,2016,55(11):1987-1992. [9]Allenbach Y,Leroux G,Suárez-Calvet X,et al.Dermatomyositis With or Without Anti-Melanoma Differentiation-Associated Gene 5 Antibodies:Common Interferon Signature but Distinct NOS2 Expression[J].Am J Pathol,2016,186(3):691-700. [10]Wong V,Ho SO,Yip R.Myositis-specific autoantibodies and their clinical associations in Idiopathic Inflammatory Myopathies[J].Acta Neurol Scand,2021,143(2):131-139. [11]Fiorentino D,Chung L,Zwerner J,et al.The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5(CADM-140):a retrospective study[J].Journal of the American Academy of Dermatology,2011,65(1):25-34. [12]李梦圆,陈斌锋.抗MDA5阳性的特发性炎性肌病的临床特征[J].广东医学,2020,7(41):683-687. [13]陈芳,王冬雪.血清抗黑色素瘤分化相关基因抗体检测在多发性肌炎/皮肌炎患者中的意义[J].中华风湿病学杂志,2012,1(16):13-18. [14]陈志涵,高飞.皮肌炎并发纵隔气肿的临床特点[J].中华临床免疫和变态反应杂志,2018,5(12):532-536. [15]Kim Y,Sykes AJ,Tugnet N,et al.Digital ulcerations in anti-MDA5 dermatomyositis:Complete resolution following treatment with cyclophosphamide[J].Australasian Journal of Dermatology,2020,61(2):e251-e252. [16]郭子维,王燕.皮肌炎合并纵隔气肿患者的临床特点及血清学特征[J].中华风湿病学杂志,2015,9(19):592-597. [17]Liao AP,Salajegheh M,Nazareno R,et al.Interferon β is associated with type 1 interferon-inducible gene expression in dermatomyositis[J].Annals of the Rheumatic Diseases,2011,70(5):831. [18]Fujiki Y,Kotani T,Isoda K,et al.Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients[J].Modern Rheumatology,2017,28(1):1-8. [19]Gono T,Kawaguchi Y,Ozeki E,et al.Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis[J].Japanese Journal of Rheumatology,2011,21(2):223-227. [20]Pacot L,Pouchot J,Prost ND,et al.Interstitial Lung Disease-Complicated Anti-MDA5 Antibody in Clinically Amyopathic Dermatomyositis Patients:Report of Two Cases With Distinct Clinical Features[J].Frontiers in Medicine,2020(7):77. [21]Ye Y,Fu Q,Wang R,et al.Serum KL‐6 level is a prognostic marker in patients with anti‐MDA5 antibody‐positive dermatomyositis associated with interstitial lung disease[J].Journal of Clinical Laboratory Analysis,2019,33(8):e22978. [22]Horai Y,Koga T,Fujikawa K,et al.Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5(MDA5)antibody-positive dermatomyositis[J].Modern Rheumatology,2015,25(1):85-89. [23]Lam SC,Yuen H.Unilateral Eyelid Swelling as a Sign of Antimelanoma Differentiation-Associated Gene 5(Anti-MDA5)-Antibody-Positive Dermatomyositis[J].Ophthalmic Plastic&Reconstructive Surgery,2018,34(6):e209-e211. [24]Cafardi JM,Sami N.Intravenous Immune Globulin in Amyopathic Dermatomyositis-Report of Two Cases and Review of the Literature[J].Open Rheumatology Journal,2015,9(1):77-81. [25]Endo Y,Koga T,Suzuki T,et al.Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis:A case report[J].Medicine,2018,97(15):e0436. [26]Yamagata A,Arita M,Tanaka A,et al.Therapeutic plasma exchange for clinically amyopathic dermatomyositis (CADM) associated with rapidly progressive interstitial pneumonia[J].J Clin Apher,2020,35(5):435-443. [27]Kato M,Ikeda K,Kageyama T,et al.Successful Treatment for Refractory Interstitial Lung Disease and Pneumomediastinum With Multidisciplinary Therapy Including Tofacitinib in a Patient With Anti-MDA5 Antibody-Positive Dermatomyositis[J].Journal of Clinical Rheumatology,2020,publish ahead of print. [28]Takatani A,Koga T,Fujita Y,et al.Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis[J].Clinical Immunology,2020(215):108451. [29]Koichi Y,Aya Y,Megumi U,et al.A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab,in addition to standard immunosuppressive treatment[J].Japanese Journal of Rheumatology,2017,27(3):536-540. [30]Moghadam-Kia S,Oddis CV,Aggarwal R.Modern Therapies for Idiopathic Inflammatory Myopathies(IIMs):Role of Biologics[J].Clinical Reviews in Allergy&Immunology,2016,52(1):1-7.